Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144326 | 0.82 | KMT2A (0.65) | HTR7HTR2BGAAKMT2AMEN1 | |
| SCHEMBL26121816 | 0.80 | HTR7 (0.58) | HTR7HTR2BGAAKMT2AMEN1 | |
| SCHEMBL4919502 | 0.78 | HTR7 (0.57) | HTR7HTR2BGAAKMT2AMEN1 | |
| SCHEMBL10708943 | 0.78 | HTR7 (0.57) | HTR7HTR2BGAAKMT2AMEN1 | |
| SCHEMBL20781244 | 0.76 | EGFR (0.46) | GAAKMT2AMEN1PDK2EGFR | |
| SCHEMBL26120364 | 0.74 | HTR2B (0.56) | HTR7HTR2BGAAPDK2MAPT | |
| SCHEMBL26120994 | 0.74 | PDK2 (0.48) | HTR7HTR2BGAAPDK2EGFR | |
| SCHEMBL30571876 | 0.74 | PDK2 (0.48) | HTR7HTR2BGAAPDK2EGFR | |
| SCHEMBL26118036 | 0.73 | TSHR (0.57) | GAALMNAPDK2EGFRMAPT | |
| SCHEMBL26116182 | 0.72 | PDK2 (0.47) | HTR2BGAAPDK2EGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | ASTELLAS PHARMA INC. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-20080161419-A1 | Prophylactic Antimigraine Agents | ASTELLAS PHARMA INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852129-A1 | REMEDY FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1716867-A1 | PREVENTIVES FOR MIGRAINE | Astellas Pharma Inc. (JP) | 2006-11-02 | — | — | EP | disclosed |
| CN-1842517-A | Fluorene derivatives | ASTELLAS PHARMA INC (JP) | 2006-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161419-A1 | Prophylactic Antimigraine Agents | HTR2B, HTR7, HTR1A | HTR7 2/4885HTR2B 1/4885GAA 3854/4885 |
| US-20080200551-A1 | Flourene Derivative | HTR2B, HTR7, HTR2C | HTR7 2/4885HTR2B 1/4885GAA 4616/4885 |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | HTR7, HTR5A, HTR3B | HTR7 1/4885HTR2B 4/4885GAA 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.